# Comparison of Different Dose of Anti-T Lymphocyte Globulin (ATLG) in Haploidentical HSCT for GVHD Prophylaxis

> **NCT06525519** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 104 (estimated)

## Conditions studied

- Hematopoietic Stem Cell Transplantation

## Interventions

- **DRUG:** ATLG
- **DRUG:** ATLG

## Key facts

- **NCT ID:** NCT06525519
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07-31
- **Primary completion:** 2025-07-31
- **Final completion:** 2026-07-31
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2024-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06525519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06525519, "Comparison of Different Dose of Anti-T Lymphocyte Globulin (ATLG) in Haploidentical HSCT for GVHD Prophylaxis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06525519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*